New test to support Chronic Myelomonocytic Leukaemia diagnosis
From November 4th, our HMDS Lab at King’s College Hospital will be offering a new immunophenotyping test to support the clinical and morphological diagnosis of Chronic Myelomonocytic Leukemia (CMML).
The same test can also be used for the differential diagnosis of monocytosis.
More details
This assay provides assessment of monocyte subsets for the investigation of persistent monocytosis (peripheral blood monocytes ≥ 0.5×109/L and monocytes ≥10% of total white blood cell count). It offers flow cytometric differentiation of a CMML diagnosis from other causes of monocytosis such as reactive monocytosis and myeloproliferative neoplasms (MPNs) in both peripheral blood and bone marrow aspirates, using a threshold of 94% classical monocytes (cMo, CD14++/CD16-) of total monocytes.
In addition to the recommended panel, we have added supplementary markers to enable reflex testing should this be required. This modified panel has been validated for use within our laboratory to support a differential diagnosis of CMML, and we are currently in the process of gaining extension to our UKAS scope for this assay.
This assay may be performed on PB or BM samples with at least 1ml of fresh specimen in EDTA required. For test selection on arrival within the SE-HMDS, ‘Immunophenotyping’ should be indicated on the request form, samples should be accompanied by unstained slides as per usual immunophenotyping requests, and clinical indication of ‘persistent monocytosis’ with a summary of WBC and monocyte counts with any relevant history/investigations must be provided in the clinical details section of the request form.
Please note that this assay is for diagnostic assessment only and is not indicated for follow-up/post-treatment samples.
Contact Rob Dunn if you have any questions on robert.dunn@nhs.net
